Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix We remain disciplined and shareholder-focused in our capital allocation Investing in the business Investments in organic business USD 9bn R&D¹ USD 1.4bn capital investments Value-creating bolt-ons USD 30bn (approx.) since 2018² 1. Core R&D actuals 2021. 2. Until Q4 2021. 3. Announced on December 16, 2021. 21 Investor Relations | Q4 2021 Results Returning to shareholders Capital allocation priorities Growing annual dividend in CHF USD 7.4bn paid out in 2021; proposed DPS increase +3% CHF; +6% USD Share buybacks USD 2.8bn executed in 2021 USD 15bn (up to; by end 2023)³ NOVARTIS | Reimagining Medicine

View entire presentation